Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients

Objective: Considering the important role of serum soluble receptor for advanced glycation end product (sRAGE/RAGE)-ligand system in rheumatoid arthritis (RA), this study aimed to evaluate serum sRAGE levels in RA patients compared to healthy subjects and to assess whether there is an association be...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2019-11, Vol.29 (6), p.943-948
Main Authors: Jafari Nakhjavani, Mohammad Reza, Jafarpour, Mahdi, Ghorbanihaghjo, Amir, Abedi Azar, Sima, Malek Mahdavi, Aida
Format: Article
Language:English
Subjects:
Adult
advanced glycation end products (AGEs,)
Arthritis, Rheumatoid - blood
Biomarkers - blood
Cross-Sectional Studies
disease activity
Female
Glycation End Products, Advanced - blood
Humans
Male
Middle Aged
Receptor for Advanced Glycation End Products - blood
Rheumatoid arthritis
soluble receptor for AGEs (sRAGE)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Considering the important role of serum soluble receptor for advanced glycation end product (sRAGE/RAGE)-ligand system in rheumatoid arthritis (RA), this study aimed to evaluate serum sRAGE levels in RA patients compared to healthy subjects and to assess whether there is an association between sRAGE levels and disease characteristics in RA. Methods: In this cross-sectional study, 60 RA patients according to the ACR/EULAR 2010 criteria and 30 age- and sex-matched healthy controls were included. In patients, clinical examination was performed and disease activity score 28 (DAS-28) measure of disease activity was assessed. Serum sRAGE level was measured using ELISA kit. Results: The mean ± SD age of patients and controls was 54.86 ± 11.65 and 50.71 ± 3.72 years, respectively). Serum sRAGE level was significantly higher in RA patients (median [25th and 75th percentiles], 1000.3 [792.00, 1486.8]) compared to healthy controls (median [25th and 75th percentiles], 293.25 [220.35, 364.24]) (p 
ISSN:1439-7595
1439-7609
DOI:10.1080/14397595.2018.1551107